Kai-ping W. Chang
Experienced in Periventricular Heterotopia

Kai-ping W. Chang

No.201, Shipai Rd, 
Beitou, TPQ, TW 
Experienced in Periventricular Heterotopia
No.201, Shipai Rd, 
Beitou, TPQ, TW 
OverviewLocationsClinical Research

Overview

Kai-ping Chang practices in Beitou, Taiwan. Mr. Chang is rated as an Experienced expert by MediFind in the treatment of Periventricular Heterotopia. His top areas of expertise are Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Oral Squamous Cell Carcinoma, Glossectomy, and Laryngectomy.

His clinical research consists of co-authoring 221 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Periventricular Heterotopia.

Gender
Male

Locations

No.201, Shipai Rd, Beitou, TPQ 11217, Taiwan
Other Locations
Taoyuan Branch, Taoyuan City, TNQ, Taiwan
201, Sec. 2, Shih Pai Road, Taipei, TNQ 11217, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Drug, Combination product
Study Drugs: ASP-1929, Docetaxel, Cetuximab, Methotrexate, Paclitaxel
Study Phase: Phase 3

221 Total Publications

Prognostic utility of 18F-FDG PET/MRI with intravoxel incoherent motion imaging in nasopharyngeal carcinoma.
Prognostic utility of 18F-FDG PET/MRI with intravoxel incoherent motion imaging in nasopharyngeal carcinoma.
Journal: European journal of nuclear medicine and molecular imaging
Published: March 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Chang's expertise for a condition
ConditionClose
    View All 26 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile